Zebrafish Drug Efficacy and Safety Evaluation Service

BioVenic offers professional zebrafish drug efficacy and safety evaluation services that integrate transgenic model technology and high-throughput screening systems for early preclinical drug research. As a gold-standard vertebrate model for preclinical validation, zebrafish bridges the technical gap between limited in vitro cell assays and costly rodent experiments. It mimics human multi-organ metabolism and pathological features to intuitively identify compound-induced multi-organ toxicity and validate targeted therapeutic efficacy, effectively lowering research risks and boosting preclinical screening success rates.

Ideal Projects We Support

• Small-Molecule Candidate Drug De-Risking: Complete high-throughput safety screening of synthetic small-molecule compounds, identify potential developmental toxicity, organ toxicity and genotoxicity risks at an early stage, and eliminate unsafe candidates.
• Cardiovascular Drug Preclinical Verification: Evaluate the efficacy and cardiac safety of new cardiovascular therapeutic drugs, detect drug-induced arrhythmia risk and myocardial functional changes, supporting cardiovascular drug efficacy optimization.
• Genetically Modified Drug Model Verification: Combine customized zebrafish knockout/overexpression disease models to verify the targeted therapeutic efficacy of precision drugs and explore drug action mechanisms for specific genetic diseases.

Fig 1. Evaluation of anti-angiogenic activity of natural drugs by transgenic zebrafish models. ¹

Common Challenges We Help Address

• Subtle low-dose organ toxicity and delayed developmental damage induced by candidate drugs are difficult to distinguish from normal developmental phenotypes, leading to missed judgment of potential drug risks.
• Traditional manual observation cannot quantitatively analyze drug efficacy indicators such as angiogenesis inhibition and myocardial contractility, resulting in subjective and inaccurate efficacy evaluation results.
• High-throughput batch screening is prone to individual developmental differences of zebrafish embryos, causing unstable repeatability of multi-batch experimental data.
• It is difficult to synchronously realize high-efficiency toxicity risk detection and precise efficacy verification, resulting in cumbersome preclinical drug screening processes.
• Lack of standardized transgenic disease model construction schemes, limiting the targeted efficacy verification accuracy of specific therapeutic drugs.

Zebrafish Drug Efficacy and Safety Evaluation Service

• Toxicity & Safety Assessment

Applicable Scenarios: Early safety de-risking of new drug candidates. Suitable for systematic detection of compound-induced developmental toxicity, specific organ toxicity and genetic toxicity, applicable to batch safety screening of natural products and synthetic small-molecule drugs.

Technical Capabilities: Adopt 96/384-well high-throughput screening system, set multi-dose gradient exposure groups, combine morphological observation and molecular biomarker detection, comprehensively evaluate drug developmental teratogenicity, hepatotoxicity, nephrotoxicity and genotoxicity risks.

Deliverables: Drug toxicity phenotypic observation data, organ damage quantitative analysis results, genotoxicity test reports, toxicity dose-effect relationship curve and compound safety evaluation conclusion.

• Cardiovascular Screening

Applicable Scenarios: Preclinical cardiac safety and cardiovascular drug efficacy verification. Focus on evaluating drug-induced cardiac functional abnormalities and the therapeutic efficacy of cardiovascular protective drugs, covering arrhythmia risk and myocardial activity detection.

Technical Capabilities: Rely on transgenic cardiovascular fluorescent zebrafish models, monitor real-time heart rate, myocardial contractility and vascular developmental changes, quantitatively identify drug cardiotoxicity and verify vascular protection efficacy.

Deliverables: Cardiac functional dynamic monitoring data, arrhythmia risk assessment results, vascular developmental phenotypic analysis and cardiovascular drug safety & efficacy comprehensive report.

• Disease Efficacy Screening

Applicable Scenarios: Targeted therapeutic efficacy verification of disease-specific drugs. Applied to efficacy evaluation of anti-tumor angiogenesis, neurodegeneration protection and anti-inflammatory antioxidant drugs, supporting drug functional optimization.

Technical Capabilities: Construct zebrafish tumor metastasis, neuroinflammation and oxidative damage disease models, adopt high-content imaging technology to quantitatively analyze drug intervention effects on disease phenotypes and clarify drug therapeutic mechanisms.

Deliverables: Disease phenotype improvement data, drug efficacy quantitative statistical results, therapeutic mechanism analysis and targeted drug efficacy verification report.

• Advanced Model Generation

Applicable Scenarios: Customized disease model construction for precision drug research. Suitable for targeted gene knockout and overexpression model development, supporting mechanism research and efficacy verification of gene-targeted therapeutic drugs.

Technical Capabilities: Adopt mature gene editing technology to construct stable zebrafish genetic disease models, customize specific gene modification schemes according to drug targets, and provide long-term reusable experimental models for drug research.

Deliverables: Gene editing model identification data, stable strain construction report, model phenotypic verification results and customized drug screening model supporting services.

Standardized Service Workflow

All zebrafish drug evaluation experiments follow BioVenic's unified RUO-level standardized operating specifications to ensure high repeatability and accuracy of preclinical screening data.

1. Experimental Scheme Customization: Formulate exclusive screening schemes according to drug attributes and research demands, confirm model type, dose gradient and detection indicators.
2. Zebrafish Model Grouping & Exposure: Screen healthy zebrafish embryos with consistent developmental status, set blank control and drug exposure groups for standardized compound intervention.
3. Real-Time Phenotypic Monitoring: Conduct continuous microscopic imaging and behavioral monitoring to record drug-induced toxicity phenotypes and disease improvement effects.
4. Multi-Index Quantitative Detection: Complete organ toxicity index, cardiac function and disease efficacy quantitative detection via molecular staining and high-content analysis technology.
5. Data Analysis & Mechanism Summary: Compare phenotypic differences between groups, fit dose-effect relationships, and summarize drug safety and efficacy characteristics.
6. Professional Report Delivery: Integrate all experimental data to form a complete preclinical drug efficacy and safety evaluation report.

Why Choose BioVenic

• Professional Preclinical R&D Team: Specialized in zebrafish pharmaceutical toxicology and efficacy research, proficient in transgenic model application, high-content imaging analysis and preclinical drug data interpretation.
• Customized Drug Screening Solutions: Flexibly adjust detection indicators and model types for different drug types such as natural products and small-molecule compounds, adapting to diversified research goals.
• High-Throughput & Visualized Technology: Equipped with mature high-throughput screening platform and transgenic fluorescent models, realizing intuitive and quantitative drug safety and efficacy evaluation.

Core Application Scenarios

• Natural Product Drug Development

Screen active ingredients of natural medicines, verify anti-tumor, anti-inflammatory and antioxidant efficacy, and eliminate toxic and harmful components to optimize natural drug formulas.

• New Candidate Drug Early De-Risking

Complete batch safety screening of synthetic compounds, identify potential organ toxicity and genetic risks at an early stage, reduce late-stage drug development failure rate.

• Cardiovascular Drug Safety Optimization

Evaluate cardiac side effects and protective efficacy of new cardiovascular drugs, provide data support for dosage optimization and safety improvement.

• Precision Drug Mechanism Research

Combine gene-edited disease models to explore drug targeted action pathways, providing in vivo experimental basis for precision drug research and development.

Published Research Background

As shown in a peer-reviewed, zebrafish xenograft models are applied to assess the anti-tumor efficacy of natural products, with two experimental sequences of pre-treatment and post-transplantation intervention. The workflow includes fluorescent labeling of human cancer cells, microinjection into zebrafish embryos, natural product administration, and fluorescence microscopy observation of tumor proliferation and metastasis. Benefiting from immature embryonic immunity without transplant rejection, this model enables intuitive in vivo anti-cancer screening.

BioVenic provides professional in vivo anti-tumor efficacy screening services for natural product and small-molecule drug development projects.

Fig 2. Evaluation of anti-tumor activity of natural drugs through zebrafish xenograft models. ¹

Frequently Asked Questions

1. What types of drugs are suitable for zebrafish efficacy and safety evaluation?
   This service is widely applicable to natural plant medicines, traditional Chinese medicine monomers, synthetic small-molecule drugs and cardiovascular therapeutic drugs, covering anti-tumor, anti-inflammatory and neuroprotective drug research scenarios.
2. What advantages does transgenic zebrafish have over ordinary zebrafish models?
   Transgenic fluorescent zebrafish can realize specific visualization of blood vessels, heart and other organs, accurately quantify drug efficacy and subtle organ damage, and greatly improve the accuracy of drug screening.
3. What organ toxicity can be detected in the safety assessment service?
   Our service covers developmental teratogenicity, hepatotoxicity, nephrotoxicity and genotoxicity, realizing full-coverage systematic safety detection of common drug toxic risks.
4. How to ensure the stability of high-throughput screening data?
   We adopt unified embryo screening standards and multi-group parallel control design, strictly control experimental environment parameters, and eliminate individual differences to ensure stable and repeatable screening results.

Partner with BioVenic

BioVenic specializes in comprehensive Zebrafish Drug Efficacy and Safety Evaluation Service, catering to diverse preclinical research and drug development needs. We acknowledge that systematic efficacy validation and safety profiling are indispensable for screening promising drug candidates and minimizing subsequent research risks. Our proficient research team utilizes optimized zebrafish experimental platforms to deliver accurate, repeatable, and data-driven evaluation results. Feel free to contact us to inquire about our service scope, discuss your unique project designs, or obtain a precise formal quote. Our professional team will provide full-cycle technical support to empower your drug development journey.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services